Literature DB >> 8654159

Alpha but not beta interferon is useful in chronic active hepatitis due to hepatitis C virus. A prospective, double-blind, randomized study.

E Villa1, P Trande, A Grottola, P Buttafoco, A M Rebecchi, T Stroffolini, F Callea, A Merighi, L Camellini, P Zoboli, R Cosenza, L Miglioli, P Loria, R Iori, N Carulli, F Manenti.   

Abstract

Interferon-alpha has been widely used in chronic hepatitis C, but controlled studies with intramuscular interferon-beta are lacking. We therefore performed a prospective, double-blind, randomized study comparing intramuscular IFN-alpha and -beta in patients with chronic hepatitis C. Sixty patients were randomly assigned to receive 3 MU thrice weekly intramuscularly of either recombinant IFN-alpha or leukocyte IFN-alpha or fibroblast IFN-beta for six months. Nine of 20 patients (45.0%) in the recombinant IFN, 5/19 (26.3%) in the leukocyte IFN, and none in the IFN-beta group had a complete response during therapy (recombinant IFN vs IFN-beta: P < 0.01). Only in IFN-alpha-treated patients, was infection with a single HCV genotype (type 2a or 2b) associated with significantly better long-term outcome. IFN-alpha is useful in chronic hepatitis C while intramuscular IFN-beta interferon does not exert any beneficial effect. This is probably due to an insufficient bioavailability of IFN-beta when given intramuscularly.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8654159     DOI： 10.1007/bf02088244

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


  26 in total

1.  Comparative study on the antiviral activity of tumor necrosis factor (TNF)-alpha, lymphotoxin/TNF-beta, and IL-1 in WISH cells.

Authors:  V Ruggiero; G Antonelli; M Gentile; G Conciatori; F Dianzani
Journal:  Immunol Lett       Date:  1989-05       Impact factor: 3.685

Review 2.  Histological grading and staging of chronic hepatitis.

Authors:  K Ishak; A Baptista; L Bianchi; F Callea; J De Groote; F Gudat; H Denk; V Desmet; G Korb; R N MacSween
Journal:  J Hepatol       Date:  1995-06       Impact factor: 25.083

Review 3.  Rapid evolution of RNA genomes.

Authors:  J Holland; K Spindler; F Horodyski; E Grabau; S Nichol; S VandePol
Journal:  Science       Date:  1982-03-26       Impact factor: 47.728

4.  Effect of interferon administration on serum hepatitis C virus RNA in patients with chronic hepatitis C.

Authors:  K Chayama; S Saitoh; Y Arase; K Ikeda; T Matsumoto; Y Sakai; M Kobayashi; M Unakami; T Morinaga; H Kumada
Journal:  Hepatology       Date:  1991-06       Impact factor: 17.425

5.  A randomized controlled trial of interferon alfa-2b as therapy for chronic non-A, non-B hepatitis.

Authors:  G Saracco; F Rosina; M R Torrani Cerenzia; V Lattore; L Chiandussi; V Gallo; R Petrino; A G De Micheli; E Donegani; A Solinas
Journal:  J Hepatol       Date:  1990       Impact factor: 25.083

6.  Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C.

Authors:  M Shindo; A M Di Bisceglie; L Cheung; J W Shih; K Cristiano; S M Feinstone; J H Hoofnagle
Journal:  Ann Intern Med       Date:  1991-11-01       Impact factor: 25.391

7.  Detection of hepatitis C virus RNA in serum of patients with chronic hepatitis C treated with interferon-alpha.

Authors:  H Hagiwara; N Hayashi; E Mita; K Ueda; T Takehara; A Kasahara; H Fusamoto; T Kamada
Journal:  Hepatology       Date:  1992-01       Impact factor: 17.425

8.  Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution.

Authors:  M Martell; J I Esteban; J Quer; J Genescà; A Weiner; R Esteban; J Guardia; J Gómez
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

9.  Long-term follow-up of patients with chronic hepatitis C treated with alpha-interferon.

Authors:  M Shindo; A M Di Bisceglie; J H Hoofnagle
Journal:  Hepatology       Date:  1992-06       Impact factor: 17.425

10.  Administration of fibroblast interferon to patients with advanced breast cancer: possible effects on skin metastasis and on hormone receptors.

Authors:  P Pouillart; T Palangie; M Jouve; E Garcia-Giralt; W H Fridman; H Magdelenat; E Falcoff; A Billiau
Journal:  Eur J Cancer Clin Oncol       Date:  1982-10
View more
  5 in total

1.  High viral eradication with a daily 12-week natural interferon-beta treatment regimen in chronic hepatitis C patients with low viral load. IFN-beta Research Group.

Authors:  Y Shiratori; R Nakata; N Shimizu; H Katada; S Hisamitsu; E Yasuda; M Matsumura; T Narita; K Kawada; M Omata
Journal:  Dig Dis Sci       Date:  2000-12       Impact factor: 3.199

2.  Differences between interferon-alpha and -beta treatment for patients with chronic hepatitis C virus infection.

Authors:  N Furusyo; J Hayashi; M Ohmiya; Y Sawayama; Y Kawakami; I Ariyama; N Kinukawa; S Kashiwagi
Journal:  Dig Dis Sci       Date:  1999-03       Impact factor: 3.199

Review 3.  Is interferon-beta an alternative treatment for chronic hepatitis C?

Authors:  Ricardo Moreno-Otero; María Trapero-Marugán; Elena Gómez-Domínguez; Luisa García-Buey; José A Moreno-Monteagudo
Journal:  World J Gastroenterol       Date:  2006-05-07       Impact factor: 5.742

Review 4.  Safety of interferon beta treatment for chronic HCV hepatitis.

Authors:  D Festi; L Sandri; G Mazzella; E Roda; T Sacco; T Staniscia; S Capodicasa; A Vestito; A Colecchia
Journal:  World J Gastroenterol       Date:  2004-01       Impact factor: 5.742

Review 5.  Interferons and their use in persistent viral infections.

Authors:  Stéphane Chevaliez; Jean-Michel Pawlotsky
Journal:  Handb Exp Pharmacol       Date:  2009
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.